caa a22 4500 475819306 CHVBK 20180406123818.0 cr unu---uuuuu 170329e20001201xx s 000 0 eng 10.1007/s002280000230 doi (NATIONALLICENCE)springer-10.1007/s002280000230 Schindel Fritz Biometrics Department, Aventis Behring GmbH, PO Box 1230, 35002 Marburg, Germany aut Consideration of endogenous backgrounds in pharmacokinetic analyses: a simulation study [Elektronische Daten] [Fritz Schindel] Abstract.: Objective: The pharmacokinetic analysis of biologic compounds is frequently disturbed by the presence of endogenous levels, which cannot be discerned from exogenous levels. The frequently used method of subtracting baseline levels from subsequent measurements was compared to a fully adjusted regression model in a simulation study. Methods: Simulations (5,000 each) were carried out for a standard one-compartment model with rich (n=10) and poor (n=6) postdose sampling, using unweighted as well as two-weighted types of non-linear regression. Results: Whereas the fully adjusted model performed properly across various scenarios, the subtraction method showed a noteworthy bias (up to 14%) for area under the curve (AUC) and elimination half-life with weighted non-linear regression. For estimation of the Cmax parameter using any weighting scheme, and of any parameter using unweighted non-linear regression, the two methods performed equally well. As expected, poor in contrast to rich sampling resulted in larger coefficients of variation, but also in increasing failures (4.4%) of the regression algorithm (failure to converge, negative Cmax or half-life) for the subtraction method when it was combined with the weighting scheme giving highest weight to small concentrations. Conclusion: The risk of biased results may result from the subtraction method, which may also affect the analysis of dose linearity, bioequivalence and population kinetic studies with biologic compounds. When background endogenous levels are not negligible, a fully adjusted model is recommended. Springer-Verlag, 2000 Pharmacokinetics Biologic compounds Endogenous background nationallicence European Journal of Clinical Pharmacology Springer-Verlag 56/9-10(2000-12-01), 685-688 0031-6970 56:9-10<685 2000 56 228 https://doi.org/10.1007/s002280000230 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280000230 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Schindel Fritz Biometrics Department, Aventis Behring GmbH, PO Box 1230, 35002 Marburg, Germany aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 56/9-10(2000-12-01), 685-688 0031-6970 56:9-10<685 2000 56 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer